GlassScriptPhysician profile
Jenna Boyne
NPI 1558910422
$6,823.69
in general payments reported to CMS, 2019-2025
20 companies · $2,675 in 2025
The $2,675 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.79 · 2024: $4,135 · 2025: $2,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,532 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,531.50 |
| Education | $292.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.66 | 2024-2025 | |
| Janssen Biotech, INC. | $961.16 | 2024-2025 | Tremfya |
| Ucb, INC. | $846.37 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $792.52 | 2024-2025 | Dupixent, Libtayo |
| Incyte Corporation | $530.31 | 2024-2025 | Opzelura |
| Amgen INC. | $450.50 | 2024-2025 | Otezla, Otezla |
| Leo Pharma INC. | $323.29 | 2024-2025 | Adbry, Spevigo, Anzupgo |
| Lilly USA, LLC | $318.14 | 2024-2025 | Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $303.35 | 2024-2025 | |
| Genzyme Corporation | $247.40 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $237.89 | 2024-2025 | |
| Dermavant Sciences, INC. | $175.90 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.64 | 2024-2025 | Spevigo |
| Galderma Laboratories, L.P. | $125.00 | 2024 | |
| Organon LLC | $111.34 | 2025 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $76.00 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $47.74 | 2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $30.56 | 2025 | Sotyktu |
| Sandoz INC. | $20.10 | 2024 | Hyrimoz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.82 | 2024 | Jublia, Arazlo, Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Boyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.